Revisit ligand-receptor interaction at the human vasopressin V2 receptor: A kinetic perspective

The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials

BMC Gastroenterology ◽

10.1186/s12876-015-0297-z ◽

2015 ◽

Vol 15 (1) ◽

Cited By ~ 30

Author(s):

Long Yan ◽

Feng Xie ◽

Jiongjiong Lu ◽

Qingqiang Ni ◽

Changying Shi ◽

...

Keyword(s):

Randomized Controlled Trials ◽

Meta Analysis ◽

Controlled Trials ◽

Receptor Antagonists ◽

Randomized Controlled ◽

Vasopressin V2 Receptor ◽

V2 Receptor

Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist

Nature Medicine ◽

10.1038/nm935 ◽

2003 ◽

Vol 9 (10) ◽

pp. 1323-1326 ◽

Cited By ~ 431

Author(s):

Vincent H Gattone ◽

Xiaofang Wang ◽

Peter C Harris ◽

Vicente E Torres

Keyword(s):

Receptor Antagonist ◽

Disease Development ◽

Cystic Disease ◽

Renal Cystic Disease ◽

Vasopressin V2 Receptor ◽

V2 Receptor ◽

Nephrogenic Diabetes Insipidus Due to a New Mutation of the Arginine Vasopressin V2 Receptor Gene in a Girl Presenting with Non-Accidental Injury

Annals of Clinical Biochemistry International Journal of Laboratory Medicine ◽

10.1177/000456329903600616 ◽

1999 ◽

Vol 36 (6) ◽

pp. 779-782 ◽

Cited By ~ 9

Author(s):

C. P. C. Seem ◽

J. F. B. Dossetor ◽

M. D. Penney

Keyword(s):

Diabetes Insipidus ◽

Arginine Vasopressin ◽

Nephrogenic Diabetes Insipidus ◽

Receptor Gene ◽

Accidental Injury ◽

New Mutation ◽

Vasopressin V2 Receptor ◽

V2 Receptor ◽

Non Accidental Injury ◽

V2 Receptor Gene

VPA-985, a Nonpeptide Orally Active and Selective Vasopressin V2 Receptor Antagonist

Advances in Experimental Medicine and Biology - Vasopressin and Oxytocin ◽

10.1007/978-1-4615-4871-3_55 ◽

1998 ◽

pp. 439-443 ◽

Cited By ~ 31

Author(s):

Peter S. Chan ◽

Joseph Coupet ◽

Hyung C. Park ◽

Fong Lai ◽

Dale Hartupee ◽

...

Keyword(s):

Receptor Antagonist ◽

Vasopressin V2 Receptor ◽

V2 Receptor ◽

Orally Active ◽

Mutations in the Vasopressin V2 Receptor and Aquaporin-2 Genes in Twelve Families with Congenital Nephrogenic Diabetes Insipidus

Advances in Experimental Medicine and Biology - Vasopressin and Oxytocin ◽

10.1007/978-1-4615-4871-3_49 ◽

1998 ◽

pp. 387-390 ◽

Cited By ~ 8

Author(s):

Rosa Vargas-Poussou ◽

Lionel Forestier ◽

Marie Dominique Dautzenberg ◽

Patrick Niaudet ◽

Michèle Déchaux ◽

...

Keyword(s):

Diabetes Insipidus ◽

Nephrogenic Diabetes Insipidus ◽

Aquaporin 2 ◽

Vasopressin V2 Receptor ◽

Congenital Nephrogenic Diabetes Insipidus ◽

V2 Receptor

Dynamics of the G Protein-coupled Vasopressin V2 Receptor Signaling Network Revealed by Quantitative Phosphoproteomics

Molecular & Cellular Proteomics ◽

10.1074/mcp.m111.014613 ◽

2011 ◽

Vol 11 (2) ◽

pp. M111.014613 ◽

Cited By ~ 57

Author(s):

Jason D. Hoffert ◽

Trairak Pisitkun ◽

Fahad Saeed ◽

Jae H. Song ◽

Chung-Lin Chou ◽

...

Keyword(s):

G Protein ◽

Signaling Network ◽

Receptor Signaling ◽

Vasopressin V2 Receptor ◽

V2 Receptor ◽

G Protein Coupled ◽

Quantitative Phosphoproteomics

Effect of SR121463, a Selective Non-Peptide Vasopressin V2 Receptor Antagonist, in a Rabbit Model of Ocular Hypertension

Journal of Ocular Pharmacology and Therapeutics ◽

10.1089/jop.2000.16.203 ◽

2000 ◽

Vol 16 (3) ◽

pp. 203-216 ◽

Cited By ~ 12

Author(s):

FREDERIC LACHERETZ ◽

ALAIN BARBIER ◽

CLAUDINE SERRADEIL-LE GAL ◽

PIERRE-PAUL ELENA ◽

JEAN-PIERRE MAFFRAND ◽

...

Keyword(s):

Receptor Antagonist ◽

Ocular Hypertension ◽

Rabbit Model ◽

Vasopressin V2 Receptor ◽

V2 Receptor ◽

The role of conserved extracellular cysteine residues in vasopressin V2 receptor function and properties of two naturally occurring mutant receptors with additional extracellular cysteine residues

FEBS Letters ◽

10.1016/s0014-5793(99)01764-0 ◽

2000 ◽

Vol 466 (1) ◽

pp. 101-106 ◽

Cited By ~ 19

Author(s):

Ralf Schülein ◽

Kerstin Zühlke ◽

Alexander Oksche ◽

Ricardo Hermosilla ◽

Jens Furkert ◽

...

Keyword(s):

Cysteine Residues ◽

Receptor Function ◽

Naturally Occurring ◽

Vasopressin V2 Receptor ◽

V2 Receptor ◽

Mutant Receptors

Tolvaptan, an Oral Vasopressin V2 Receptor Antagonist for Heart Failure?

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2007.10.006 ◽

2007 ◽

Vol 50 (6) ◽

pp. 904-907

Author(s):

Arthur Greenberg

Keyword(s):

Heart Failure ◽

Receptor Antagonist ◽

Vasopressin V2 Receptor ◽

V2 Receptor ◽